Evidence-Based Complementary and Alternative Medicine / 2019 / Article / Tab 4

Review Article

An Overview of the Randomized Placebo-Controlled Trials of Chinese Herbal Medicine Formula Granules

Table 4

Comparison of the effectiveness rate between CHM formula granules and placebo.

Study IDTreatmentPlaceboP value

HBV carrier: Reduction of within-group HBV DNA levels by more than 2lgIU/ml
He JS 201238/17421.845/935.380.001
Li HZ 201237/19119.374/944.260.002
Ni W 20156/4015.002/2010.000.59
Peng DT 201615/4434.092/238.700.04
Xing YF 201237/19119.379/1874.81<0.001
Meta-analysis RR and 95% CI: 4.64 ; I2 = 0%

Non-alcoholic fatty liver disease: Reduction in ALT by >50% after 12-week treatment
Cheng Y 201733/4082.5021/4052.000.006

Depression: Reduction in Edinburgh Postnatal Depression Scale (EPDS)≥50
Xu F 2013-140/5080.0024/5048.000.001
Xu F 201335/4577.7818/4540.330.0004

Fever: Reduction in fever, and resolution of some cold symptoms
Cheng Y 201639/4195.1226/4065.850.003
Xie JH 201745/4893.7544/4891.670.7
Meta-analysis(random) RR and 95% CI: 3.78 ; I2 = 70%

Migraine: Reduction in frequency/duration of headaches by >50% after 12-week treatment
Fu CH 2014101/12978.2949/6476.560.79
Fu CH 201492/12971.3246/6471.880.94

AIDS: Increase in CD4 levels by >30 after 6-month treatment
Li Y 201214/3638.896/3616.670.04

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.